Mullane K M, Pinto A
Fed Proc. 1987 Jan;46(1):54-62.
Vasoactive mediators play an important role in the control of coronary vascular tone. Arachidonic acid (AA) metabolites and endothelium-derived vasoactive factors have been implicated in coronary vasoregulation. AA can be metabolized via three separate routes in blood vessels, mediated by cyclooxygenase, lipoxygenase, and cytochrome P-450-dependent monooxygenase enzymes. AA can evoke endothelium-dependent relaxations that are due in part to the formation of cytochrome P-450-dependent metabolites, inasmuch as drugs that modify cytochrome P-450 activity produce parallel changes in endothelium-dependent relaxations to AA. Moreover, some cytochrome P-450-derived metabolites formed biologically cause relaxations of isolated blood vessels. A cytochrome P-450-dependent pathway does not appear to contribute to endothelium-dependent relaxations induced by acetylcholine, which suggests that there may be a number of endothelium-derived relaxing factors (EDRFs). In addition, two endothelium-derived contractile factors have been described, including an unidentified cyclooxygenase metabolite of AA and a polypeptide isolated from cultured cells. As both prostaglandin I2 and acetylcholine-induced EDRF also inhibit platelet aggregation, endothelial injury and loss of these factors may predispose to vasospasm precipitated by release of platelet-derived mediators such as thromboxane A2 (TXA2) and 5-hydroxytryptamine. Unstable angina may be a clinical syndrome in which these events occur, which can be alleviated by inhibition of platelet activation and TXA2 formation with aspirin. Attenuation of endothelium-dependent relaxations can also occur without loss of endothelial cells. Neutrophil-endothelium interactions, precipitated by an ischemic episode, may initiate endothelial dysfunction and underlie the development of vasospasm in some conditions. Whether increased production of endothelium-derived contractile factors also occurs in vasospastic conditions remains to be determined.
血管活性介质在冠状动脉血管张力的调控中发挥着重要作用。花生四烯酸(AA)代谢产物和内皮源性血管活性因子与冠状动脉血管调节有关。AA可通过血管中由环氧化酶、脂氧化酶和细胞色素P-450依赖性单加氧酶介导的三条不同途径进行代谢。AA可引起内皮依赖性舒张,部分原因是细胞色素P-450依赖性代谢产物的形成,因为改变细胞色素P-450活性的药物会使对AA的内皮依赖性舒张产生平行变化。此外,一些生物形成的细胞色素P-450衍生代谢产物可引起离体血管舒张。细胞色素P-450依赖性途径似乎并不参与乙酰胆碱诱导的内皮依赖性舒张,这表明可能存在多种内皮源性舒张因子(EDRFs)。此外,还描述了两种内皮源性收缩因子,包括一种未明确的AA环氧化酶代谢产物和一种从培养细胞中分离出的多肽。由于前列腺素I2和乙酰胆碱诱导的EDRF也抑制血小板聚集,这些因子的内皮损伤和丧失可能易导致由血小板衍生介质如血栓素A2(TXA2)和5-羟色胺释放所引发的血管痉挛。不稳定型心绞痛可能是一种发生这些事件的临床综合征,可通过使用阿司匹林抑制血小板活化和TXA2形成来缓解。内皮依赖性舒张的减弱也可能在没有内皮细胞丧失的情况下发生。缺血发作引发的中性粒细胞与内皮的相互作用可能引发内皮功能障碍,并在某些情况下成为血管痉挛发生的基础。在血管痉挛性疾病中是否也会出现内皮源性收缩因子产生增加仍有待确定。